- Home
- CDRE vs WGS Comparison
CDRE vs WGS Comparison
Compare CDRE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- WGS
- Stock Information
- Founded
- CDRE 2012
- WGS 2017
- Country
- CDRE United States
- WGS United States
- Employees
- CDRE N/A
- WGS N/A
- Industry
- CDRE Industrial Specialties
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- CDRE Health Care
- WGS Technology
- Exchange
- CDRE Nasdaq
- WGS Nasdaq
- Market Cap
- CDRE 1.4B
- WGS 1.5B
- IPO Year
- CDRE 2021
- WGS N/A
- Fundamental
- Price
- CDRE $32.53
- WGS $68.43
- Analyst Decision
- CDRE Buy
- WGS Strong Buy
- Analyst Count
- CDRE 5
- WGS 5
- Target Price
- CDRE $39.75
- WGS $67.00
- AVG Volume (30 Days)
- CDRE 186.5K
- WGS 753.8K
- Earning Date
- CDRE 11-06-2024
- WGS 10-29-2024
- Dividend Yield
- CDRE 1.08%
- WGS N/A
- EPS Growth
- CDRE N/A
- WGS N/A
- EPS
- CDRE 0.83
- WGS N/A
- Revenue
- CDRE $516,159,999.00
- WGS $267,228,000.00
- Revenue This Year
- CDRE $19.96
- WGS $43.70
- Revenue Next Year
- CDRE $7.73
- WGS $16.78
- P/E Ratio
- CDRE $39.28
- WGS N/A
- Revenue Growth
- CDRE 7.18
- WGS 29.41
- 52 Week Low
- CDRE $29.19
- WGS $1.29
- 52 Week High
- CDRE $40.28
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- CDRE 33.41
- WGS 51.05
- Support Level
- CDRE $32.64
- WGS $71.45
- Resistance Level
- CDRE $36.01
- WGS $82.18
- Average True Range (ATR)
- CDRE 1.45
- WGS 7.58
- MACD
- CDRE -0.33
- WGS -1.36
- Stochastic Oscillator
- CDRE 3.41
- WGS 17.21
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.